Pharmafile Logo
T40 2022 Cover
Diversity, Equity and Inclusion
Communiqué 53 Cover Image
- PMLiVE

Braftovi

- PMLiVE

Pfizer turns to cancer immunotherapies

Signs deal with French company Cellectis

- PMLiVE

SMC: Celgene’s Abraxane ‘too expensive’ for Scotland

But medicines watchdog backs Sovaldi, Invokana, Defitelio, Relvar Ellipta

- PMLiVE

Pfizer appoints diabetes expert Morris Birnbaum

He takes up post as chief scientific officer for cardiovascular and metabolic diseases

- PMLiVE

ASCO: AstraZeneca shows off cancer immunotherapy

MEDI4736 could rival Merck & Co’s anti-PD1 inhibitor pembrolizumab

- PMLiVE

ASCO: Merck’s anti-PD1 impresses in skin and lung cancer

Promising MK-3475 immunotherapy to be known as pembrolizumab

- PMLiVE

US cancer ads come under fire

Study concludes that cancer advertisements tug at the heartstrings without providing sufficient information

- PMLiVE

Bruno Strigini leaves Merck & Co for Novartis

Will head up an oncology business boosted by the acquisition of GSK's portfolio

- PMLiVE

ASCO: AZ’s ovarian cancer combination aces trial

Olaparib/cediranib combo demonstrates progression-free survival of 17.7 months

- PMLiVE

GSK and Bayer strike new biotech cancer deals

Agreements with Orion and Adaptimmune aimed at strengthening their respective oncology pipelines

- PMLiVE

Interview: AstraZeneca’s Susan Galbraith

As ASCO commences the company's VP of oncology talks to PMLiVE about its pipeline prospects in cancer

- PMLiVE

Pfizer abandons AZ takeover bid – for now

Deadline for deal passes after four rejected offers

- PMLiVE

No mass revolt from AZ shareholders on Pfizer takeover

Company’s decision to stand firm is applauded by investors

Subscribe to our email news alerts

Latest jobs from #PharmaRole

Latest content

Latest intelligence

Quick links